ArticleJournal of virology2002
Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles.
Article in Journal of virology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 72 citations in OpenAlex.
- Tailored Viral-like Particles as Drivers of Medical Breakthroughs.International journal of molecular sciences · 2024Review
- An IL-12-Based Nanocytokine Safely Potentiates Anticancer Immunity through Spatiotemporal Control of Inflammation to Eradicate Advanced Cold Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Influenza Virus Carrying a Codon-Reprogrammed Neuraminidase Gene as a Strategy for Live Attenuated Vaccine.Vaccines · 2023Article
- Respiratory Viruses and Virus-like Particle Vaccine Development: How Far Have We Advanced?Viruses · 2023Review
- A chemical method for generating live-attenuated, replication-defective DNA viruses for vaccine development.Cell reports methods · 2022Article
- Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2.Journal of microbiology (Seoul, Korea) · 2022Review
- Membrane Microvesicles as Potential Vaccine Candidates.International journal of molecular sciences · 2021Review
- A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.Journal of virology · 2021Article
- A Replication-Defective Influenza Virus Vaccine Confers Complete Protection against H7N9 Viral Infection in Mice.Vaccines · 2020Article
- Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.Frontiers in immunology · 2020Review
- Construction & establishment of two minigenome rescue systems for Chandipura virus driven by recombinant vaccinia virus expressing T7 polymerase.The Indian journal of medical research · 2017Article
- Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus.Vaccine · 2015Article
- Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza Virus.Journal of vaccines & vaccination · 2015Article
- Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.Vaccine · 2015Article
- Influenza vaccines: a moving interdisciplinary field.Viruses · 2014Review
- A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine.Vaccine · 2012Article
- A replication-incompetent PB2-knockout influenza A virus vaccine vector.Journal of virology · 2012Article
- Antigen quality determines the efficiency of antitumor immune responses generated in the absence of regulatory T cells.Cancer gene therapy · 2010Article
- Rationalizing the development of live attenuated virus vaccines.Nature biotechnology · 2010Review
- Cytopathic mechanisms of HIV-1.Virology journal · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the success of influenza virus vaccines in reducing severe illness, their efficacy is suboptimal. We describe here the immunogenicity and protective capacity of replication-incompetent influenza virus-like particles (VLPs) which were generated entirely from cDNAs and lacked either the entire NS gene (encoding both the NS1 and NS2 protein) or only the NS2 gene. In mammalian cells infected with NS gene-deficient VLPs, the nucleoprotein, but not other viral proteins including hemagglutinin (HA) and neuraminidase (NA), was detected. In contrast, cells infected with VLPs expressing NS1 but not NS2 (NS2 knockout) expressed multiple viral proteins, including HA and NA. When challenged with lethal doses of an antigenically homologous mouse-adapted influenza virus, 94% of mice vaccinated with the NS2-knockout VLPs survived, compared with less than 10% of those given the NS-deficient VLPs. These results demonstrate the potential of replication-incompetent NS2-knockout VLPs as novel influenza vaccines and perhaps also as vectors to express genes from entirely unrelated pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.